These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 31308634)

  • 1. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease.
    Zhang DY; Zhu L; Liu HN; Tseng YJ; Weng SQ; Liu TT; Dong L; Shen XZ
    Drug Des Devel Ther; 2019; 13():2249-2270. PubMed ID: 31308634
    [No Abstract]   [Full Text] [Related]  

  • 2. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
    J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis.
    Li H; Xi Y; Xin X; Tian H; Hu Y
    Biomed Pharmacother; 2020 Apr; 124():109915. PubMed ID: 31986416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FXR-Dependent Modulation of the Human Small Intestinal Microbiome by the Bile Acid Derivative Obeticholic Acid.
    Friedman ES; Li Y; Shen TD; Jiang J; Chau L; Adorini L; Babakhani F; Edwards J; Shapiro D; Zhao C; Carr RM; Bittinger K; Li H; Wu GD
    Gastroenterology; 2018 Dec; 155(6):1741-1752.e5. PubMed ID: 30144429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice.
    Li X; Zhao W; Xiao M; Yu L; Chen Q; Hu X; Zhao Y; Xiong L; Chen X; Wang X; Ba Y; Guo Q; Wu X
    J Ethnopharmacol; 2022 Aug; 294():115333. PubMed ID: 35500802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pure total flavonoids from citrus attenuate non-alcoholic steatohepatitis via regulating the gut microbiota and bile acid metabolism in mice.
    He B; Jiang J; Shi Z; Wu L; Yan J; Chen Z; Luo M; Cui D; Xu S; Yan M; Zhang S; Chen Z
    Biomed Pharmacother; 2021 Mar; 135():111183. PubMed ID: 33401222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soyasaponin A
    Xiong F; Zheng Z; Xiao L; Su C; Chen J; Gu X; Tang J; Zhao Y; Luo H; Zha L
    Mol Nutr Food Res; 2021 Jul; 65(14):e2100067. PubMed ID: 34047448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice.
    Porras D; Nistal E; Martínez-Flórez S; Olcoz JL; Jover R; Jorquera F; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Mol Nutr Food Res; 2019 Apr; 63(8):e1800930. PubMed ID: 30680920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease.
    Petrov PD; García-Mediavilla MV; Guzmán C; Porras D; Nistal E; Martínez-Flórez S; Castell JV; González-Gallego J; Sánchez-Campos S; Jover R
    Mol Nutr Food Res; 2019 Oct; 63(20):e1900487. PubMed ID: 31322321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.
    Wang W; Zhao J; Gui W; Sun D; Dai H; Xiao L; Chu H; Du F; Zhu Q; Schnabl B; Huang K; Yang L; Hou X
    Br J Pharmacol; 2018 Feb; 175(3):469-484. PubMed ID: 29139555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
    Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
    Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
    Chen J; Thomsen M; Vitetta L
    J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.
    Jiao N; Baker SS; Chapa-Rodriguez A; Liu W; Nugent CA; Tsompana M; Mastrandrea L; Buck MJ; Baker RD; Genco RJ; Zhu R; Zhu L
    Gut; 2018 Oct; 67(10):1881-1891. PubMed ID: 28774887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.
    Ho PP; Steinman L
    Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.
    Jiang C; Xie C; Li F; Zhang L; Nichols RG; Krausz KW; Cai J; Qi Y; Fang ZZ; Takahashi S; Tanaka N; Desai D; Amin SG; Albert I; Patterson AD; Gonzalez FJ
    J Clin Invest; 2015 Jan; 125(1):386-402. PubMed ID: 25500885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
    J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.
    Sun L; Cai J; Gonzalez FJ
    Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):335-347. PubMed ID: 33568795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of Ilexhainanoside D and ilexsaponin A
    Zhao W; Xiao M; Yang J; Zhang L; Ba Y; Xu R; Liu Z; Zou H; Yu P; Wu X; Chen X
    Phytomedicine; 2019 Oct; 63():153039. PubMed ID: 31387054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.